natgillin/translations-raw huggingface dataset:
Do not use in pregnant and lactating bitches (see section 4.7).
Ne uporabljajte pri brejih psicah in psicah v laktaciji (glejte poglavje 4. 7).
Special precautions for use in animals Halogenated volatile anaesthetics can react with dry carbon dioxide (CO2) absorbents to produce carbon monoxide (CO) that may result in elevated levels of carboxyhaemoglobin in some dogs.
Posebni previdnostni ukrepi za uporabo pri živalih Halogenirani hlapni anestetiki lahko reagirajo s suhimi absorbenti ogljikovega dioksida (CO2), tako da nastane ogljikov monoksid (CO), ki lahko pri nekaterih psih povzroči zvišano raven karboksihemoglobina.
Rare cases of excessive heat production, smoke and/ or fire in the anaesthetic machine have been reported during the use of a desiccated CO2 absorbent and sevoflurane.
Poročajo o redkih primerih čezmernega nastajanja toplote, dima in/ ali ognja v anestezijskem aparatu pri uporabi osušenega absorberja za CO2 in sevoflurana.
An unusual decrease in the expected depth of anaesthesia compared to the vaporiser setting may indicate excessive heating of the CO2 absorbent canister.
Neobičajno zmanjšanje pričakovane globine anestezije glede na nastavitev hlapilnika utegne
The colour indicator of most CO2 absorbents does not necessarily change as a result of desiccation.
Zato odsotnosti pomembne
Therefore, the lack of significant colour change should not be taken as an assurance of adequate hydration.
2/ 24 spremembe barve ne smete razumeti, kot da to zagotavlja zadostno hidracijo.
2/ 24 1,1,3,3,3-pentafluoro-2-(fluoromethoxy)propene (C4H2F6O), also known as Compound A, is produced when sevoflurane interacts with soda lime or barium hydroxide.
1, 1, 3, 3, 3- pentafluoro- 2 - (fluorometoksi) propen (C4H2F6O), znan tudi kot spojina A, nastaja, kadar sevofluran reagira z zmesjo kalcijevega hidroksida z natrijevim ali kalijevim hidroksidom ali barijevim hidroksidom.
Since the reaction of carbon dioxide with absorbents is exothermic, this temperature increase will be determined by the quantities of CO2 absorbed, which in turn will depend on fresh gas flow in the anaesthetic circle system, metabolic status of the dog and ventilation.
Ker je reakcija ogljikovega dioksida z absorbenti eksotermna, bo to zvišanje temperature določala količina absorbiranega CO2, le- ta pa bo odvisna od pretoka svežega plina v anestezijskem krožnem sistemu, presnovnega stanja psa in dihanja.
If malignant hyperthermia develops, the anaesthetic supply should be interrupted immediately and 100% oxygen administered using fresh anaesthetic hoses and a rebreathing bag.
Če se razvije maligna hipertermija, je treba takoj prekiniti dovajanje anestetika in dati 100- odstotni kisik z uporabo svežih anestezijskih cevi in dihalnega balona.
Compromised or debilitated dogs Doses of sevoflurane may need adjustment for geriatric or debilitated dogs.
Pri geriatričnih ali izčrpanih psih bo mogoče treba prilagoditi odmerke sevoflurana.
2.8% to 3.1% in premedicated geriatric dogs and 3.2 to 3.3% in unpremedicated geriatric dogs).
Odmerke, potrebne za vzdrževanje anestezije, bo pri geriatričnih psih mogoče treba zmanjšati za približno 0, 5% (t. j., 2, 8% do 3, 1% pri geriatričnih psih s premedikacijo in 3, 2 do 3, 3% pri geriatričnih psih brez premedikacije).
Special precautions to be taken by the person administering the veterinary medicinal product to animals In order to minimise exposure to sevoflurane vapour, the following recommendations are made: • Use a cuffed endotracheal tube when possible for the administration of SevoFlo during maintenance anaesthesia. • Avoid using masking procedures for prolonged induction and maintenance of general anaesthesia. • Ensure that operating rooms and animal recovery areas are provided with adequate ventilation or scavenging systems to prevent the accumulation of anaesthetic vapour. • All scavenging/ extraction systems must be adequately maintained. • Pregnant and breast-feeding women should not have any contact with the product and should avoid operating rooms and animal recovery areas. • Care should be taken when dispensing SevoFlo, with immediate removal of any spillage. • Do not inhale the vapour directly.
• Kadar je možno, uporabljajte za uporabo SevoFlo med vzdrževalno anestezijo endotrahealni tubus z mešičkom. • Ne uporabljajte postopkov z masko za dolgotrajno uvajanje in vzdrževanje splošne anestezije. • Poskrbite, da bodo operacijske sobe in prostori za prebujanje živali opremljene z ustreznimi prezračevalnimi ali čistilnimi sistemi, ki bodo preprečevali kopičenje hlapov anestetika. • Vse sisteme za prečiščevanje zraka je treba ustrezno vzdrževati. • Nosečnice in doječe matere ne smejo priti v stik z zdravilom in se morajo izogibati operacijskim sobam in prostorom za prebujanje živali.
3/ 24 • Avoid contact by mouth. • Halogenated anaesthetic agents may induce liver damage.
3/ 24 • Pri pripravi SevoFlo moramo biti previdni, morebitno razlito zdravilo je treba nemudoma odstraniti. • Ne vdihavajte hlapov neposredno. • Izogibajte se stiku preko ust. • Halogenirana anestetična sredstva lahko povzročijo okvaro jeter.
This is an idiosyncratic response very occasionally seen after repeated exposure. • From an environmental point of view, it is considered good practice to use charcoal filters with scavenging equipment.
To je idiosinkratičen odziv, ki ga po ponovnem izpostavljanju vidimo precej redko. • S stališča varstva okolja velja za dobro prakso, da pri opremi za čiščenje zraka uporabljamo filtre iz oglja.
4.7 Use during pregnancy or lactation
4. 7 Uporaba v obdobju brejosti ali laktacije
Use only according to the risk/ benefit assessment of the responsible veterinarian.
Uporabite le v skladu z oceno razmerja korist/ tveganje odgovornega veterinarja.
4/ 24 4.8 Interaction with other medicinal products and other forms of interaction
4/ 24 4. 8 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Intravenous Anaesthetics:
Intravenski anestetiki:
Phenothiazines and alpha-2-agonists:
Fenotiazini in alfa- 2- agonisti:
Sevoflurane is compatible with phenothiazines and alpha-2-agonists commonly used in veterinary practice.
Sevofluran je kompatibilen s fenotiazini in alfa- 2- agonisti, ki se navadno uporabljajo v veterinarski praksi.
Α lpha-2-agonists have an anaesthetic sparing effect and therefore the dose of sevoflurane should be reduced accordingly.
Alfa- 2- agonisti varčujejo z anestetikom, zato moramo ustrezno zmanjšati odmerek sevoflurana.
Limited data are available on the effects of the highly potent alpha-2- agonists (medetomidine and romifidine) as premedication.
O učinkih zelo močnih alfa- 2- agonistov (medetomidina in romifidina) kot zdravil za premedikacijo so na voljo omejeni podatki.
Bradycardia may develop when alpha-2-agonists are used with sevoflurane.
Kadar se uporabljajo alfa- 2- agonisti s sevofluranom, se utegne razviti bradikardija.
In a laboratory study, the use of an acepromazine/ oxymorphone/ thiopental/ sevoflurane anaesthetic regimen resulted in prolonged recoveries in all the dogs treated, compared to recoveries in dogs anaesthetised with sevoflurane alone.
V laboratorijski raziskavi je uporaba anestezijske sheme z acepromazinom/ oksimorfonom / tiopentalom / sevofluranom povzročila podaljšano prebujanje pri vseh psih, ki so dobili ta zdravila, v primerjavi s psi, ki so jih anestezirali samo s sevofluranom.
Inspired Concentration:
Koncentracija v vdihanem zraku:
For mask induction using sevoflurane, inspired concentrations of 5 to 7% sevoflurane with oxygen are employed to induce surgical anaesthesia in the healthy dog.
Za uvod v anestezijo z masko in sevofluranom se za uvedbo kirurške anestezije pri zdravem psu uporabljajo koncentracije 5 do 7% sevoflurana v vdihanem zraku.
5/ 24 Surgical levels of anaesthesia in the healthy dog may be maintained with inhaled concentrations of 3.3 to 3.6% in the presence of premedication.
5/ 24 Kirurške ravni anestezije pri zdravih psih lahko vzdržujemo s koncentracijami 3, 3 do 3, 6% v vdihanem zraku ob premedikaciji.
In the absence of premedication, inhaled concentrations of sevoflurane in the range 3.7 to 3.8% will provide surgical levels of anaesthesia in the healthy dog.
Če premedikacije ni, bodo inhalirane koncetracije sevoflurana v mejah 3, 7 do 3, 8% pri zdravem psu povzročile kirurške ravni anestezije.
Anaesthetic regimens that include opioid, alpha-2-agonist, benzodiazepine or phenothiazine premedication will allow the use of lower sevoflurane maintenance concentrations.
Anestezijske sheme, ki vključujejo premedikacijo z opioidi, alfa- 2- agonisti, benzodiazepini ali fenotiazini, dopuščajo uporabo nižjih vzdrževalnih koncentracij sevoflurana.
Therefore, respiration must be monitored closely and supported when necessary with supplementary oxygen and/ or assisted ventilation.
Zato je treba dihanje skrbno spremljati in ga podpirati, če je potrebno, z dodatnim kisikom in/ ali asistirano ventilacijo.
Pharmacotherapeutic group: inhalation anaesthetic, ATCvet code:
Inhalacijski anestetik, oznaka ATCvet:
The Minimum Alveolar Concentration (MAC) of sevoflurane in dogs is 2.36%.
Minimalna alveolarna koncentracija (MAC) sevoflurana pri psih je 2, 36%.
Multiples of MAC are used as a guide for surgical levels of anaesthesia, which are typically 1.3 to 1.5 times the MAC value.
Mnogokratniki MAC se uporabljajo kot smernica za kirurške ravni anestezije, ki so tipično 1, 3 do 1, 5- kratnik vrednosti MAC.
Sevoflurane may increase intracranial pressure at concentrations of 2.0 MAC and above under normal partial pressures of carbon dioxide (normocapnia), but intracranial pressure has been shown to remain within normal range at sevoflurane concentrations of up to 1.5 MAC if hypocapnia is induced by hyperventilation.
Sevofluran lahko zviša intrakranialni tlak pri koncentracijah 2, 0 MAC in več, pri normalnih parcialnih tlakih ogljikovega dioksida (normokapnija), vendar se je pokazalo, da intrakranialni tlak ostane v normalnih mejah pri koncentracijah sevoflurana do 1, 5 MAC, če se hipokapnija inducira s hiperventilacijo.
Respiratory depression may lead to respiratory acidosis and respiratory arrest (at sevoflurane concentrations of 2.0 MAC and above) in spontaneously breathing dogs.
Depresija dihanja lahko povzroči respiracijsko acidozo in zastoj dihanja (pri koncentracijah servoflurana 2, 0 MAC in višjih) pri psih, ki spontano dihajo.
6/ 24 Concentrations of sevoflurane below 2.0 MAC result in a small net increase in total liver blood flow.
6/ 24 pomembno spremenjena.
A minimal amount of sevoflurane is required to be dissolved in the blood before the alveolar partial pressure is in equilibrium with the arterial partial pressure because of the low solubility of sevoflurane in blood (blood/ gas partition coefficient at 30°C is 0.63 to 0.69).
Zaradi majhne topnosti sevoflurana v krvi (porazdelitveni koeficient med krvjo in plinom pri 30 °C je 0, 63 do 0, 69) se mora v krvi raztopiti minimalna količina sevoflurana, preden se alveolarni parcialni tlak uravnovesi z arterijskim parcialnim tlakom.
Sevoflurane is metabolised to a limited extent in the dog (1 to 5%).
Sevofluran se pri psu presnavlja v omejenem obsegu (1 do 5%).
In dogs exposed to 4% sevoflurane for 3 hours, mean peak maximum serum fluoride concentrations of 20.0 ± 4.8 µmol/ l have been observed after 3 hours of anaesthesia.
Pri psih, izpostavljenih 4- odstotnemu sevofluranu 3 ure dolgo, so opazovali srednji vrh najvišjih serumskih koncentracij fluorida 20, 0 ± 4, 8 µmol/ l po 3 urah anestezije.
Shelf-life of the veterinary medicinal product as packaged for sale:
Rok uporabnosti zdravila v pakiranju za produjo:
Do not refrigerate.
Ne shranjujete v hladilniku.
7/ 24 6.5 Nature and composition of immediate packaging
7/ 24 6. 5 Vrsta ovojnine in vsebina
SevoFlo is presented in a cardboard box containing a 250 ml polyethylene naphthalate (PEN) bottle with a Quik-Fil closure.
SevoFlo dobavljajo v kartonasti škatli, ki vsebuje 250- mililitrsko steklenico iz polietilennaftalata (PEN) z zaporko Quik- Fil.
Abbott Laboratories Ltd Queenborough Kent ME11 5EL United Kingdom
Abbott Laboratories Ltd Queenborough Ken ME11 5EL Velika Britanija
11 December 2002 Date of last renewal:
11. december 2002 Datum zadnjega podaljšanja:
8/ 24 ANNEX II
8/ 24 DODATEK II
MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
9/ 24 A IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJE
10/ 24 ANNEX III
10/ 24 DODATEK III
12/ 24 PARTICULARS TO APPEAR ON THE OUTER PACKAGE
12/ 24 PODATKI NA ZUNANJI OVOJNINI
SevoFlo 100% Inhalation vapour, liquid for dogs. sevoflurane
SevoFlo 100- odstotna para za inhaliranje, tekočina za pse. sevofluran
13/ 24 Do not use in dogs less than 12 weeks of age.
Ne uporabljajte pri psih, mlajših od 12 tednov.
For operator warnings - read the package leaflet before use.
13/ 24 Pred uporabo preberite navodilo za uporabo, kjer boste našli opozorila za kirurga.
Any unused veterinary medicinal product or waste materials derived from the veterinary medicinal product should be disposed of in accordance with local regulations.
Vsako neporabljeno veterinarsko zdravilo ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z nacionalnimi zahtevami.
14/ 24 PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE
PRIMARNI OVOJNINI
17/ 24 PACKAGE LEAFLET SevoFlo Inhalation vapour, liquid for dogs, 100% sevoflurane
17/ 24 NAVODILO ZA UPORABO SevoFlo Para za inhaliranje, tekočina za pse, 100% sevofluran
SevoFlo 100% Inhalation vapour, liquid for dogs. sevoflurane
SevoFlo 100% para za inhaliranje, tekočina za pse.
18/ 24 Sevoflurane causes dose-dependant respiratory depression, therefore respiration should be closely monitored during sevoflurane anaesthesia and the inspired concentration of sevoflurane adjusted accordingly.
18/ 24 zraku.
If any serious effects or other effects not mentioned in this leaflet are noticed, please ensure the veterinary surgeon is informed.
Če opazite kakršne koli resne neželene učinke ali druge učinke, ki niso omenjeni v teh navodilih za uporabo, obvestite svojega veterinarja.
For mask induction using sevoflurane, inspired concentrations of 5 to 7% sevoflurane with oxygen are employed to induce surgical anaesthesia in the healthy dog.
Za uvod v anestezijo z masko in sevofluranom se za uvedbo kirurške anestezije pri zdravem psu uporabljajo koncentracije 5 do 7% servoflurana v vdihanem zraku.
Surgical levels of anaesthesia in the healthy dog may be maintained with inhaled concentrations of 3.3 to 3.6% in the presence of premedication.
Kirurške ravni anestezije pri zdravih psih lahko vzdržujemo z inhaliranimi koncentracijami 3, 3 do 3, 6% ob premedikaciji.
In the absence of premedication, inhaled concentrations of sevoflurane in the range of 3.7 to 3.8% will provide surgical levels of anaesthesia in the healthy dog.
Če premedikacije ni, bodo inhalirane koncentracije sevoflurana v mejah 3, 7 do 3, 8% pri zdravem psu povzročile kirurške ravni anestezije.
The
Uporaba sredstev za uvod v anestezijo, ki se injicirajo, brez premedikacije le malo vpliva na koncentracije sevoflurana, ki so potrebne za vzdrževanje.
19/ 24 use of injectable induction agents without premedication has little effect on the concentrations of sevoflurane required for maintenance.
19/ 24 Anestetične sheme, ki vključujejo premedikacijo z opioidi, alfa- 2- agonisti, benzodiazepini ali fenotiazini, dopuščajo uporabo nižjih vzdrževalnih koncentracij sevoflurana.
Intravenous Anaesthetics:
Anestetiki za intravensko uporabo:
Limited data are available on the effects of the highly potent alpha-2- agonists (medetomidine and romifidine) as premedication.
O učinkih zelo močnih alfa- 2- agonistov (medetomidina in romifidina) kot sredstvih za premedikacijo so na voljo omejeni podatki.
In a laboratory study, the use of an acepromazine/ oxymorphone/ thiopental/ sevoflurane anaesthetic regimen resulted in prolonged recoveries in all the dogs treated, compared to recoveries in dogs anaesthetised with sevoflurane alone.
V laboratorijski raziskavi je uporaba anestezijske sheme z acepromazinom/ oksimorfonom / tiopentalom/ sevofluranom povzročila podaljšano prebujanje pri vseh psih, ki so dobili ta zdravila, v primerjavi s psi, ki so jih anestezirali samo s sevofluranom.
20/ 24 Do not store above 25°C.
20/ 24 Ne shranjujte v hladilniku.
Special precautions for use:
Posebni previdnostni ukrepi:
1,1,3,3,3-pentafluoro-2-(fluoromethoxy)propene (C4H2F6O), also known as Compound A, is produced when sevoflurane interacts with soda lime or barium hydroxide.
1, 1, 3, 3, 3- pentafluoro- 2 - (fluorometoksi) propen (C4H2F6O), znan tudi kot spojina A, nastaja, kadar sevofluran reagira z zmesjo kalcijevega hidroksida z natrijevim ali kalijevim hidroksidom ali barijevim hidroksidom.
Due to sevoflurane ’ s low solubility in blood, these haemodynamic changes may occur more rapidly than with other volatile anaesthetics.
Zaradi majhne topnosti sevoflurana v krvi lahko te hemodinamske spremembe nastopijo hitreje kot pri drugih hlapnih anestetikih.
If malignant hyperthermia develops, the anaesthetic supply should be interrupted immediately and 100% oxygen administered using fresh anaesthetic hoses and a rebreathing bag.
21/ 24 hipertermija, je treba nemudoma prekiniti dovajanje anestetika in dati 100- odstotni kisik z uporabo svežih anestezijskih cevi in dihalnega balona.
2.8 to 3.1% in premedicated geriatric dogs and 3.2 to 3.3% in unpremedicated geriatric dogs).
Odmerke, potrebne za vzdrževanje anestezije, bo pri geriatričnih psih mogoče treba zmanjšati za približno 0, 5% (t. j., 2, 8% do 3, 1% pri geriatričnih psih s premedikacijo in 3, 2 do 3, 3% pri geriatričnih psih brez premedikacije).
Use only according to the risk/ benefit assessment of the responsible veterinarian.
Uporabite le v skladu z oceno razmerja korist/ tveganje odgovornega veterinarja..
Due to sevoflurane ’ s low solubility in blood, increasing the concentration may result in rapid haemodynamic changes (dose-dependent decreases in blood pressure) compared to other volatile anaesthetics.
Zaradi majhne topnosti sevoflurana v krvi utegne zviševanje koncentracije povzročiti hitre hemodinamske spremembe (od odmerka odvisno znižanje krvnega tlaka) v primerjavi z drugimi hlapnimi anestetiki.
In order to minimise exposure to sevoflurane vapour, the following recommendations are made: • Use a cuffed endotracheal tube when possible for the administration of SevoFlo during maintenance anaesthesia. • Avoid using masking procedures for prolonged induction and maintenance of general anaesthesia. • Ensure that operating rooms and animal recovery areas are provided with adequate ventilation or scavenging systems to prevent the accumulation of anaesthetic vapour. • All scavenging/ extraction systems must be adequately maintained. • Pregnant and breast-feeding women should not have any contact with the product and should avoid operating rooms and animal recovery areas. • Care should be taken when dispensing SevoFlo, with immediate removal of any spillage. • Do not inhale the vapour directly. • Avoid contact by mouth. • Halogenated anaesthetic agents may induce liver damage.
Da bi kar najbolj zmanjšali izpostavitev hlapom sevoflurana, priporočamo naslednje: • Kadar je možno, uporabljajte za uporabo SevoFlo med vzdrževalno anestezijo endotrahealni tubus z mešičkom. • Ne uporabljajte postopkov z masko za dolgotrajno uvajanje in vzdrževanje splošne anestezije. • Poskrbite, da bodo operacijske sobe in prostori za prebujanje živali opremljene z ustreznimi prezračevalnimi ali čistilnimi sistemi, ki bodo preprečevali kopičenje hlapov anestetika. • Vse sisteme za prečiščevanje zraka je treba ustrezno vzdrževati. • Nosečnice in doječe matere ne smejo priti v stik z zdravilom in se morajo izogibati operacijskim sobam in prostorom za prebujanje živali. • Pri pripravi SevoFlo moramo biti previdni, morebitno razlito zdravilo je treba nemudoma odstraniti. • Ne vdihavajte hlapov neposredno. • Izogibajte se stiku preko ust. • Halogenirana anestetična sredstva lahko povzročijo okvaro jeter.
This is an idiosyncratic response very occasionally seen after repeated exposure.
To je idiosinkratičen odziv, ki ga po ponovnem izpostavljanju vidimo precej redko. • S stališča varstva okolja velja za dobro prakso, da pri opremi za čiščenje zraka uporabljamo filtre iz oglja.
22/ 24 • From an environmental point of view, it is considered good practice to use charcoal filters with scavenging equipment.
22/ 24 Neposredno izpostavljanje oči lahko povzroči blago draženje.
Any unused veterinary medicinal product or waste materials derived from the veterinary medicinal product should be disposed of in accordance with local regulations.
Vsako neporabljeno zdravilo ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z nacionalnimi zahtevami.
Vaccines work by ‘ teaching’ the immune system (the body’ s natural defences) how to defend itself against a disease.
Cepiva delujejo tako, da imunski sistem (naravni obrambni mehanizem telesa) „ naučijo “, kako naj se brani pred boleznijo.
When it is given to a cow, the animal’ s immune system recognises the bacteria as ‘ foreign ’ and makes antibodies against them.
Če cepivo damo kravi, njen imunski sistem prepozna bakterije kot „ tuje “ in začne tvoriti protitelesa proti njim.
The vaccine also contains an ‘ adjuvant’ (liquid paraffin) to stimulate a better response.
Cepivo vsebuje tudi „ adjuvans “ (tekoči parafin) za spodbujanje boljšega odziva.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 47 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2009 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged What benefit has Startvac shown during the studies?
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 47 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2009 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Kakšne koristi je zdravilo Startvac izkazalo med študijami?
The European Commission granted a marketing authorisation valid throughout the European Union, for Startvac to Laboratorios Hipra, S. A. on 11 February 2009.
Evropska komisija je dovoljenje za promet z zdravilom Startvac, veljavno po vsej Evropski uniji, odobrila družbi Laboratorios Hipra, S. A. dne 11/ 02/ 2009.
This summary was last updated on 11 February 2009.
Ta povzetek je bil nazadnje posodobljen 11/ 02/ 2009.
Page 2/ 2 ©EMEA 2009
Stran 2/ 2 ©EMEA 2009
Target species
Ciljna
Withdraw al period
Escherichia coli J5:
Escherichia coli J5: > 50 RED60 * Staph. aureus (CP8): > 50 RED80 **
> 50 RED60 * Staph. aureus (CP8): > 50 RED80 **
Cattle (cows and heifers)
govedo (krave in telice)
Cardboard box, glass 1 dose vial with a rubber stopper and aluminium cap
škatla iz lepenke, steklena viala z gumijastim zamaškom in aluminijasto zaporko
1 vial
1 odmerek 1 viala
EU/ 2/ 08/ 092/ 002 STARTVAC Escherichia coli J5: > 50 RED60 * Staph. aureus (CP8): > 50 RED80 **
> 50 RED60 * Staph. aureus (CP8): > 50 RED80 ** EU/ 2/ 08/ 092/ 003 STARTVAC Escherichia coli J5:
10 vials
1 odmerek 10 vial
EU/ 2/ 08/ 092/ 003 STARTVAC Escherichia coli J5: > 50 RED60 * Staph. aureus (CP8): > 50 RED80 **
> 50 RED60 * Staph. aureus (CP8): > 50 RED80 ** EU/ 2/ 08/ 092/ 004 STARTVAC Escherichia coli J5:
20 vials
1 odmerek 20 vial
EU/ 2/ 08/ 092/ 004 STARTVAC Escherichia coli J5: > 50 RED60 * Staph. aureus (CP8): > 50 RED80 **
> 50 RED60 * Staph. aureus (CP8): > 50 RED80 ** EU/ 2/ 08/ 092/ 005 STARTVAC Escherichia coli J5:
Cardboard box, glass 5 doses vial with a rubber stopper and aluminium cap
škatla iz lepenke, steklena viala z gumijastim zamaškom in aluminijasto zaporko
1 vial
5 od - 1 viala merkov
EU/ 2/ 08/ 092/ 005 STARTVAC Escherichia coli J5: > 50 RED60 * Staph. aureus (CP8): > 50 RED80 **
> 50 RED60 * Staph. aureus (CP8): > 50 RED80 ** EU/ 2/ 08/ 092/ 006 STARTVAC Escherichia coli J5:
10 vials
5 od - 10 vial merkov
EU/ 2/ 08/ 092/ 006 STARTVAC Escherichia coli J5: > 50 RED60 * Staph. aureus (CP8): > 50 RED80 **
> 50 RED60 * Staph. aureus (CP8): > 50 RED80 ** EU/ 2/ 08/ 092/ 007 STARTVAC Escherichia coli J5:
Cardboard box, glass 25 doses vial with a rubber stopper and aluminium cap
škatla iz lepenke, steklena viala z gumijastim zamaškom in aluminijasto zaporko
1 vial
25 od - 1 viala merkov